Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Members of the
p53
family of transcription factors have essential roles in tumor suppression and in development. MDM2 is an essential regulator of
p53
that can inhibit the transcriptional activity of
p53
, shuttle
p53
out of the nucleus, and target
p53
for ubiquitination-mediated degradation. Little is known about the interaction and selectivity of different members of the
p53
family (
p53
, p63, and p73) and the MDM2 family (MDM2 and
MDMX
). Here we show that the transcriptional activities of
p53
and p73, but not that of p63, were inhibited by both MDM2 and
MDMX
. Consistent with these, we found that
MDMX
can physically interact with
p53
and p73, but not with p63. Moreover, ectopically expressed MDM2 and
MDMX
could induce alterations in the subcellular localization of p73, but did not affect the subcellular localization of
p53
and p63. Finally, we demonstrate that while ARF can interact with MDM2 and inhibit the regulation of
p53
by MDM2, no interaction was found between ARF and
MDMX
. These data reveal that significant differences and selectivity exist between the regulation of different members of the
p53
family by MDM2 and
MDMX
.
...
PMID:MDM2 and MDMX can interact differently with ARF and members of the p53 family. 1122 36
While the transactivation function of the
tumor suppressor p53
is well understood, less is known about the transrepression functions of this protein. We have previously shown that
p53
interacts with the corepressor protein mSin3a (hereafter designated Sin3) in vivo and that this interaction is critical for the ability of
p53
to repress gene expression. In the present study, we demonstrate that expression of Sin3 results in posttranslational stabilization of both exogenous and endogenous
p53
, due to an inhibition of proteasome-mediated degradation of this protein. Stabilization of
p53
by Sin3 requires the Sin3-binding domain, determined here to map to the proline-rich region of
p53
, from amino acids 61 to 75. The correlation between Sin3 binding and stabilization supports the hypothesis that this domain of
p53
may normally be subject to a destabilizing influence. The finding that a synthetic mutant of
p53
lacking the Sin3-binding domain has an increased half-life in cells, compared to wild-type
p53
, supports this premise. Interestingly, unlike retinoblastoma tumor suppressor protein,
MDMX
, and p14(ARF), Sin3 stabilizes
p53
in an MDM2-independent manner. The ability of Sin3 to stabilize
p53
is consistent with the model whereby these two proteins must exist on a promoter for extended periods, in order for repression to be an effective mechanism of gene regulation. This model is consistent with our data indicating that, unlike the p300-
p53
complex, the
p53
-Sin3 complex is immunologically detectable for prolonged periods following exposure of cells to agents of DNA damage.
...
PMID:The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. 1135 5
The
p53 protein
can inhibit cell cycling or induce apoptosis, and is thus a critical regulator of tumorigenesis. This protein is negatively regulated by a physical interaction with MDM2, an E3 ubiquitin ligase. This interaction is critical for cell viability; loss of Mdm2 causes cell death in vitro and in vivo in a
p53
-dependent manner. The recently discovered MDM2-related protein MDM4 (also known as
MDMX
) has some of the same properties as MDM2. MDM4 binds and inhibits
p53
transcriptional activity in vitro. Unlike MDM2, however, MDM4 does not cause nuclear export or degradation of
p53
(refs. 9,10). To study MDM4 function in vivo, we deleted Mdm4 in mice. Mdm4-null mice died at 7.5-8.5 dpc, owing to loss of cell proliferation and not induction of apoptosis. To assess the importance of
p53
in the death of Mdm4-/- embryos, we crossed in the Trp53-null allele. The loss of Trp53 completely rescued the Mdm4-/- embryonic lethality. Thus, MDM2 and MDM4 are nonoverlapping critical regulators of
p53
in vivo. These data define a new pathway of
p53
regulation and raise the possibility that increased MDM4 levels and the resulting inactivation of
p53
contribute to the development of human tumors.
...
PMID:Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. 1152
MDMX
is a p53 binding protein, which shares a high degree of homology with MDM2, a negative regulator of the
tumor suppressor p53
.
MDMX
has been shown to counteract MDM2-dependent
p53
degradation and to stabilize
p53
in its inactive form. In this study: we identify two
MDMX
proteolytic pathways that control its intracellular levels, and show that
MDMX
post-translational processing may be regulated by
p53
. Mouse
MDMX
is cleaved in vitro and in vivo by caspase activity, between aminoacids 358 and 361, producing a p54 minor form. In addition,
MDMX
is subjected to proteasome-mediated degradation, which concurs to
MDMX
proteolysis mainly through degradation of p54. A D361A-
MDMX
mutant, resistant to caspase cleavage, exhibits prolonged intracellular lifetime in comparison to wild-type protein, indicating that caspase cleavage affects stability of
MDMX
protein probably by modulating its further degradation. Overexpression of exogenous
p53
increases the intracellular levels of p54 product. Similarly, activation of endogenous
p53
by adriamycin enhances
MDMX
cleavage and produces a marked decrease of its intracellular levels, while not affecting the D361A-
MDMX
mutant. In addition, the D361A-
MDMX
mutant lacks the ability to inhibit
p53
transactivation in respect to wild-type
MDMX
, suggesting that
MDMX
caspase cleavage play an important functional role. In conclusion, our results demonstrate that, in analogy to MDM2,
MDMX
may be subjected to proteolytic modifications that regulate its intracellular levels. Moreover, decrease of
MDMX
protein levels following
p53
activation suggests a
p53
-dependent regulatory feedback of
MDMX
function.
...
PMID:MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. 1184 Mar 32
MDMX
, an MDM2-related protein, has emerged as yet another essential negative regulator of
p53 tumor suppressor
, since loss of
MDMX
expression results in
p53
-dependent embryonic lethality in mice. However, it remains unknown why neither homologue can compensate for the loss of the other. In addition, results of biochemical studies have suggested that
MDMX
inhibits MDM2-mediated
p53
degradation, thus contradicting its role as defined in gene knockout experiments. Using cells deficient in either MDM2 or
MDMX
, we demonstrated that these two
p53
inhibitors are in fact functionally dependent on each other. In the absence of
MDMX
, MDM2 is largely ineffective in down-regulating
p53
because of its extremely short half-life.
MDMX
renders MDM2 protein sufficiently stable to function at its full potential for
p53
degradation. On the other hand,
MDMX
, which is a cytoplasmic protein, depends on MDM2 to redistribute into the nucleus and be able to inactivate
p53
. We also showed that
MDMX
, when exceedingly overexpressed, inhibits MDM2-mediated
p53
degradation by competing with MDM2 for
p53
binding. Our findings therefore provide a molecular basis for the nonoverlapping activities of these two
p53
inhibitors previously revealed in genetic studies.
...
PMID:Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. 1195 23
The p300/CBP-mediated acetylation of
p53
significantly potentiates
p53
-mediated transactivation and growth inhibition. MDM2 inhibits the acetylation of
p53
by p300/CBP through a mechanism that requires a stable
p53
-MDM2 interaction and that is sensitive to the deacetylase inhibitor, TSA.
MDMX
is an MDM2-like protein that shares with MDM2 the ability to interact with
p53
and, in turn, inhibit
p53
-mediated transcription. It was therefore of interest to determine if
MDMX
could also inhibit the acetylation of
p53
by p300/CBP. We demonstrate that
MDMX
dramatically inhibits the acetylation of
p53
induced by both endogenous and ectopically expressed p300/CBP. We also demonstrate that the
p53
-binding domain of
MDMX
is required for the
MDMX
-mediated inhibition of
p53
acetylation. Our results indicate that
MDMX
shares with MDM2 the ability to regulate a potentially important post-translational modification of
p53
. These results may have important biologic implications with respect to the
MDMX
-mediated regulation of
p53
activity during development.
...
PMID:MDMX inhibits the p300/CBP-mediated acetylation of p53. 1216 6
The MDM2 homolog
MDMX
is an important regulator of
p53
activity during embryonic development.
MDMX
inactivation in mice results in embryonic lethality in a
p53
-dependent fashion. The expression level of
MDMX
is not induced by DNA damage, and its role in stress response is unclear. We show here that ectopically expressed
MDMX
is mainly localized in the cytoplasm. DNA damage promotes nuclear translocation of
MDMX
in cells with or without
p53
. Coexpression of MDM2 or
p53
is sufficient to induce
MDMX
nuclear translocation, suggesting that activation of
p53
and induction of MDM2 expression can contribute to this process. Stable transfection of
MDMX
into U2OS cells does not alter
p53
level but results in reduced
p53
DNA-binding activity and reduced MDM2 expression. The ability of ARF (alternate reading frame of INK4a) to activate
p53
is also significantly inhibited by expression of
MDMX
. These results suggest that
MDMX
function may be regulated by DNA damage. Furthermore,
MDMX
may complement MDM2 in regulating
p53
during embryonic development due to its ability to inhibit
p53
in the presence of ARF.
...
PMID:DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. 1237 Mar 3
Several proteins with important roles in oncogenesis have been shown to regulate the function of the E2F-1 transcription factor, which is known to activate the expression of genes required for proliferation and apoptosis. Here we identify the
MDMX
oncoprotein as an E2F-1-binding factor, from a yeast-two hybrid screen using a portion of the E2F-1 protein as "bait." We demonstrate that the region within
MDMX
needed for the E2F-1:
MDMX
interaction is located in the central part of the protein, C-terminal of the
p53
-binding domain. The region within E2F-1 needed for this association is adjacent to the DNA binding domain. Further, when expressed in vivo or in vitro the
MDMX
protein migrates as two isoforms on SDS-PAGE, the faster migrating isoform having the stronger affinity for the E2F-1 proteins. It appears that this interaction reduces the ability of E2F-1 to bind DNA. Expression of
MDMX
along with E2F-1 and Dp-1 in Saos2 cells reduces the ability of E2F-1 to bind to its consensus DNA sequence, without altering E2F-1 protein levels. These data indicate that the
MDMX
protein is capable of associating with E2F-1 and negatively regulating its DNA binding ability.
...
PMID:The E2F-1 transcription factor is negatively regulated by its interaction with the MDMX protein. 1253 31
The
MDMX
gene product is related to the MDM2 oncoprotein, both of which interact with the
p53 tumor suppressor
. A novel transcript of the
MDMX
gene has been previously identified that has a short internal deletion of 68 base pairs, producing a shift in the reading frame after codon 114, resulting in the inclusion of 13 novel amino acids (after residue 114) followed by a stop codon at amino acid residue 127. This truncated
MDMX
protein, termed
MDMX
-S, represents only the
p53
binding domain and binds and inactivates
p53
better than full-length
MDMX
or MDM2. Here we show that when expressed in cells,
MDMX
-S is targeted more efficiently to the nucleus than
MDMX
.
MDMX
-S suppresses
p53
-mediated transcription from a p53 target promoter better than full-length
MDMX
. The DNA damage inducibility of these
p53
responsive promoters was suppressed better by
MDMX
-S than by
MDMX
. Analysis of the
MDMX
-S protein indicated that the 13 novel amino acids at its carboxy terminus was responsible for high affinity binding to
p53
in vitro and for high level expression of the protein in cells. Deletion of this 13 amino acid sequence resulted in a protein that was not able to bind
p53
and was not able to be expressed well in cells. Taken together, these data point to an important domain within
MDMX
-S that enables it to function well in vivo to block
p53
activity. Published 2003 Wiley-Liss, Inc.
...
PMID:Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells. 1276 90
MDM2 is an E3 ubiquitin ligase that targets
p53
for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for
p53
ubiquitination, suggesting that an additional activity of MDM2 might be required. To test this possibility, we generated a series of MDM2/
MDMX
chimeric proteins to assess the contribution of each domain of MDM2 to the ubiquitination process.
MDMX
is a close structural homolog of MDM2 that nevertheless lacks the E3 ligase activity in vivo. We demonstrate here that
MDMX
gains self-ubiquitination activity and becomes extremely unstable upon introduction of the MDM2 RFD, indicating that the RFD is essential for self-ubiquitination. This
MDMX
chimeric protein, however, is unable to ubiquitinate
p53
in vivo despite its E3 ligase activity and binding to
p53
, separating the self-ubiquitination activity of MDM2 from its ability to ubiquitinate
p53
. Significantly, fusion of the central acidic domain (AD) of MDM2 to the
MDMX
chimeric protein renders the protein fully capable of ubiquitinating
p53
, and
p53
ubiquitination is associated with
p53
degradation and nuclear export. Moreover, the AD mini protein expressed in trans can functionally rescue the AD-lacking MDM2 mutant, further supporting a critical role for the AD in MDM2-mediated
p53
ubiquitination.
...
PMID:Critical contribution of the MDM2 acidic domain to p53 ubiquitination. 1283 79
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>